Foamix Pharmaceuticals Ltd. (FOMX) Shares Down 5.5%
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) fell 5.5% during mid-day trading on Monday . The company traded as low as $8.05 and last traded at $8.05, with a volume of 180,801 shares. The stock had previously closed at $8.52.
A number of research firms have issued reports on FOMX. Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Guggenheim restated a “buy” rating and set a $10.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, May 10th.
The firm’s market cap is $245.56 million. The firm’s 50-day moving average price is $6.63 and its 200-day moving average price is $6.54.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.08. Analysts forecast that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current fiscal year.
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.